Lombard Medical product receives US approval for commercial sale

Lombard Medical, the AIM-listed medical technology firm focused on innovative vascular products, has announced that its Aorfix product has been approved for commercial sale in the US.

Lombard Medical, the AIM-listed medical technology firm focused on innovative vascular products, has announced that its Aorfix product has been approved for commercial sale in the US.

Aorfix, the company's flexible stent graft for the endovascular repair of abdominal aortic aneurysms (AAAs) was found by the US Food and Drug Administration (FDA) to treat a larger patient population than competing devices.

Lombard said: "Independent market research suggests that the U.S. market for the repair of AAAs is worth over $600m per annum, is forecast to grow at approximately 8.0% per annum."

The approval triggers receipt of the £14.1m second tranche of the two-tranche placing and subscription for funds, which will be used to launch Aorfix in the US. It also triggers the company's ability to draw down $2.5m from the $5.0m loan facility granted by its exclusive distribution partner in Japan, Medico's Hirata Inc.

"FDA approval of Aorfix is a major milestone for the company and sets the stage for the next chapter in the company's growth," said Lombard's Chief Executive Simon Hubbert.

"I would like to thank all of our employees, investigators and clinical advisors for their support and hard work, without which development and approval of Aorfix would not have been possible."

"We look forward to launching Aorfix in the U.S. through our own sales force and are confident of securing a meaningful share of this growing market."

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Nuclear power might never be popular – but now looks a good time to invest
Commodities

Nuclear power might never be popular – but now looks a good time to invest

Nuclear power gets a very bad press, but it is the ultimate renewable energy source. Interest in it is perking up again, says John Stepek. Which means…
9 Apr 2021
House prices: from boom to even bigger boom
House prices

House prices: from boom to even bigger boom

UK house prices have risen to new to record highs, says Nicole Garcia Merida. Demand continues to outpace supply, but continued low interest rates, th…
9 Apr 2021